Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment

Executive Summary

• Rapid Dose Therapeutics Corp. (RDT) announced the commercial launch of its QuickStrip™ oral thin‑film medical cannabis product in Brazil, following regulatory approval from ANVISA for both manufacturing and distribution.
• The launch is executed through a strategic partnership with U.S. distributor Nexxions and Brazilian partner Entourage Phytolab, positioning RDT to capture a rapidly growing Brazilian medical‑cannabis market estimated at US$856.5 M in 2025 and projected to reach US$1.55 B by 2034.
• The product offers rapid sublingual/buccal absorption, precise dosing, and a discreet format, addressing unmet patient needs and supporting RDT’s global growth strategy.

Key Details

• Regulatory Milestone: ANVISA granted manufacturing and distribution approval for QuickStrip™ in Brazil; also expanded permissible routes of administration to include dermatological, sublingual, buccal, and inhalation.
• Product Description: QuickStrip™ is a rapidly dissolving oral thin film delivering controlled doses of medical cannabis via sublingual or buccal absorption; intended for chronic pain, anxiety, sleep disorders, neurological symptoms, etc.
• Partnership Structure:
• Nexxions – U.S.-based distribution and marketing partner; navigated Brazilian regulatory environment and will handle market access.
• Entourage Phytolab – Brazilian pharmaceutical collaborator; co‑brands the product under the Entourage Phytolab name.
• Market Context (Brazil, early 2026):
• Population > 215 million; ~672,000 registered cannabis patients (↑56% YoY).
• Access channels: import with ANVISA authorization, pharmacy sales (49 products registered), patient‑association cultivation.
• New regulations (Jan 2026) allow patient associations, research institutes, and companies to cultivate cannabis ≤0.3 % THC, expanding access beyond severe/palliative cases.
• Industry Size & Forecast: US$856.53 M in 2025 → US$1,546.74 M by 2034 (CAGR 6.79%). Approximately 50,000 physicians actively prescribing cannabis‑based meds.
• Competitive Advantages of QuickStrip™:
• Rapid onset via oral mucosal absorption vs. oils/edibles.
• Discreet, portable format reduces stigma and improves adherence.
• Precise dosing enhances physician control and treatment consistency.
• No inhalation required – safer for patients with respiratory issues.
• Executive Comments:
• Alan Mayo (Founder & President, Nexxions) highlighted the product’s precision, discreteness, and fit for Brazilian patients.
• Caio Abreu (CEO, Entourage Phytolab) noted rapid patient relief observed in early trials.
• Mark Upsdell (CEO, Rapid Dose Therapeutics) called the launch a “significant milestone” in RDT’s global growth strategy.

Notable Quotes

• Alan Mayo, Nexxions: “The simplicity, accuracy, and reliability of QuickStrip™ make it a natural fit for patients and physicians seeking more effective, high‑quality, non‑combustible cannabis‑based therapies.”
• Caio Abreu, Entourage Phytolab: “We were impressed by how quickly patients experienced relief… the ease of use and discreet format will be a major advantage.”
• Mark Upsdell, Rapid Dose Therapeutics: “The regulatory approval and launch … represents a significant milestone in our global growth strategy.”